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Abstract
Dietary supplement use is widespread in developed nations. In particular, patients who utilize
mental health services also report frequent consumption of dietary supplements, often in relation
to management of adverse events and specifically weight gain. Weight gain induced by psychotropic
medications can further compound psychological distress and negatively influence compliance.
Here we report on four cases of social anxiety disorder treated with the atypical antipsychotic
quetiapine. Self-administration of conjugated linoleic acid and green tea extract may have influenced
objective anthropomorphic measurements; each patient had an unexpected decrease in total body
fat mass, a decrease in body fat percentage and an increase in lean body mass. Since weight gain is
a common and undesirable side-effect with psychiatric medications, our observation strongly
suggests the need for controlled clinical trials using these agents.
Background
The prevalence of dietary supplement use has increased
steadily over the last decade. Recent investigations show
that 73 percent of US adults consume at least one type of
dietary supplement during the course of a year [1]. Similar
patterns of increased self-prescription of dietary supple-
ments have also been reported among adults in Canada
and the United Kingdom [2,3]. Individuals with mental
health disorders, including anxiety and depression, are
frequent consumers of dietary supplements [4,5]. While
the efficacy of dietary and herbal supplements in mental
health care is a matter of debate, the potential to produce
adverse reactions and drug interactions is certain. Given
this reality, mental health care providers have been
directed to become informed practitioners and query
patients on the use of complementary therapies, and die-
tary supplements in particular [4,6].
In our outpatient clinic we have been inquiring on supple-
ment use among those with mood disorders and anxiety
for a number of years. In the interest of safety, we ask
patients to disclose current dietary supplement use, and
since many are taking, or will be initiating pharmacother-
apy, we recommend discussion prior to patient's self-pre-
scription with supplements.
One significant area of dietary supplement use which can
impact a psychiatric practice is that pertaining to weight
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loss. Patients with obesity-related depression and those
attempting to address or prevent antidepressant or antip-
sychotic-induced weight gain are often attracted by the
marketing of weight loss supplements. A recent audit of
commercially available weight loss supplements in 73 dif-
ferent metropolitan retail outlets revealed 402 different
products, with over 4000 separate ingredients purported
to promote weight loss [7]. The investigators point out
that among these ingredients there is little in the way of
human research in weight control to support any of these
non-prescription ingredients. Green tea, or more specifi-
cally the green tea catechins, and conjugated linoleic acid
are two weight loss ingredients with some, albeit limited,
human data. Some studies have shown that green tea
extract is associated with increased weight loss due to
enhancement of thermogenesis, a change which is gener-
ally attributed to the catechin epigallocatechin-gallate
(EGCG) [8]. For example, one human study shows that
270 mg of EGCG increased 24-hour thermogenesis
among human volunteers by over 40 percent [9]. A recent
hospital-based study in Japan used computed tomogra-
phy to determine that 690 mg of catechins and 136 mg of
EGCG resulted in the loss of more than 26 square cm of
abdominal fat over the course of three months vs. placebo
[10]. Although the results are equivocal, animal studies
and some human research suggests that conjugated lino-
leic acid (CLA) can decrease body fat mass and body fat
percentage while promoting lean body mass [11]. A recent
double-blind, placebo-controlled study at the University
of Toronto investigated a commercially available blend of
EGCG and CLA (270 mg EGCG, 3400 mg CLA daily –
abs+, Genuine Health Inc, Toronto, Canada) found that
the combination resulted in a significant body weight
loss, both as group total weight loss and mean body
weight change vs. placebo [12].
The established potential of antidepressants and the
emerging value of atypical antipsychotic medications in
the mood and anxiety disorder are tempered by the well
documented adverse effect of weight gain among users. In
fact, the increases in body weight are not only significant,
they can occur in a matter of weeks. For example, research
shows that atypical antipsychotic medication can cause a
ten pound weight gain in as little as eight weeks [13].
Other short-term studies also show a rapid weight gain in
less than 10 weeks [14]. In our experience with the mood
and anxiety we have found that the informed consent
associated with antipsychotic and antidepressant prescrip-
tion leads to an inevitable desire to initiate scientifically-
unsupported weight loss supplements in select patients.
This brief review reports on four cases where concerns
related to weight gain associated with antidepressant and
atypical antipsychotic prescription resulted in self-treat-
ment with a commercially available green tea EGCG-CLA
combination known as (abs+).
Brief report
The current observation involved four individuals whom
we identified as suffering with the mood and anxiety dis-
orders who described concerns related to weight gain and
who disclosed that they would be co-initiating use of the
previously mentioned green tea EGCG-CLA combination
(abs+) upon prescription of their medications. All
patients are routinely questioned on the current or
planned use of dietary/herbal supplements in our clinic.
While the EGCG-CLA combination is widely available in
Canadian retail outlets, it was not sold, promoted, nor
endorsed in our clinic. In a high-volume mental health
practice, four patients disclosed intent to use the EGCG-
CLA combination, and consented to objective weight-
related measurements of skinfold thickness, before, dur-
ing and at the time of discontinuing the self-prescribed
EGCG-CLA combination. These four patients were not
taking any other weight loss supplements and none made
any dramatic changes to diet or physical activity levels.
Four adults with primary generalized anxiety disorder
were treated with the atypical antipsychotic quetiapine
(Seoquel®) for periods ranging from 10–24 weeks.
Patients reported co-self-administration of 270 mg EGCG,
3400 mg CLA daily in addition to the atypical antipsy-
chotic medications and antidepressants they had taken for
treatment resistant generalized anxiety disorders. Meas-
urements of percent body fat were undertaken using the
same method, first described initially by Durnin and
Rahaman [15]. The process of measuring skin fat was
undertaken using the Holtain skinfold caliper to measure
subcutaneous adipose tissue. This process was repeated
on three successive occasions at the same spot, by the
assessor (MAK) three or more times until the assessment
was of the subjects skin fat thickness. As well, all observa-
tions were made on the right side of the body. Assess-
ments of skin thickness were undertaken at the chest,
abdomen and thigh for men and the tricep, suprailliac
spine and thigh according to the Jackson/Pollock 3 Cali-
per Method using the Jackson/Pollock equations [16]. The
skin fold thickness was estimated in the three sites and
entered into % body fat calculator using the Jakson/
Pollock3 Caliper equation and accessible from Online
Body Tracker [17]. Weight-related outcomes assessed in
our clinic are described in tables 1, 2.
Discussion
In these four adults who were taking quetiapine, the con-
current self-administration of green tea and conjugated
linoleic acid appeared to be protective against gains in
body fat. The results were fairly consistent; each had a
decrease in total body fat mass, a decrease in body fat per-
centage and an increase in lean body mass. Interestingly,
despite these desirable overall changes to body composi-
tion, there was an increase in total body weight in 2Lipids in Health and Disease 2007, 6:14 http://www.lipidworld.com/content/6/1/14
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patients. This may be, at least in part, due to the docu-
mented increases in lean body mass. Animal studies have
consistently shown an increase in lean body mass and a
reduction in body fat when CLA is incorporated into lab-
oratory chow [18]. It also highlights a previous criticism
of the weight-related endpoints used in studies on antide-
pressants and atypical antipsychotics; they have used var-
ying assessments and have relied almost exclusively on
total body weight and/or body mass index (BMI) [14].
Researchers have called for assessments that are more
standardized and specific in nature, including the body fat
and lean mass assessments used in our clinic.
The mechanisms whereby CLA and green tea EGCG can
modulate energy balance remain mostly theoretical,
although some researchers have provided insight. For
example, CLA can inhibit prostaglandin E2, a chemical
known to prevent lipolysis [18-21]. In addition, CLA may
reduce lipid uptake by the fat cell, enhance thermogenesis
in fat cells and increase the mobilization of fatty acids by
an increase in catecholamine production [22].
Experimental studies show that green tea extract high in
EGCG can directly inhibit gastric and pancreatic lipases,
increase thermogenesis and possibly prevent the enzy-
matic degradation of catechol O-methyltransferase, an
enzyme which plays a role in the respiration rate of brown
adipose tissue, while animal research indicates that EGCG
(not the related catechins) can significantly reduce food
intake and body weight [8].
Obviously this report documents only the changes in
body composition among just four adults on atypical
antipsychotics. Clearly, there are external issues which
may have changed outcome, including the evaluation of
patients who were motivated to self-administer a com-
mercial supplement. This, coupled with the awareness of
our interest in any subsequent anthropomorphic changes,
could serve to alter other weight-related lifestyle factors.
Still, we find the consistency of the results among all of
those followed to be remarkable and one which raises the
possibility of a real effect. We set out to follow these
patients with the expectation that there would be only
increases in body fat mass and body fat percentages, with
little to no change in lean body mass.
While no conclusions can be drawn, our observations
should encourage a thorough scientific investigation con-
cerning the utility of EGCG and CLA in the prevention of
psychotropic medication-induced weight gain. Rapid
weight gain among patients with mental disorders is an
extremely distressing experience. In addition to the psy-
chological fallout and potential non-compliance with
otherwise effective medications, there is also the well
known increase in risk of chronic diseases which accom-
pany body fat accumulation. Every avenue of research
should be exhausted in addressing side effects and medi-
cation-induced weight gain, including those related to the
external products which mental health patients are self-
prescribing.
Within the past five years author Alan C. Logan has been
a compensated independent consultant for Genuine
Health Inc, the company which manufactures abs+. He
holds no stock or shares and possesses no financial hold-
ings with Genuine Health. The product used is not pat-
ented or under active patent application. There are no
other competing interests to report among any of the
authors.
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Table 1: Changes to total weight, body fat percentage (BF%), body fat mass (BFM) and lean body mass (LBM)
Gender/Age Quetiapine Weeks Total Weight BF % BFM LBM
Dose/Day on abs+ Start End Start End Start End Start End
Male; 44 600 mg 24 246.4 242 45.9 42.2 113.2 102.2 133.2 139.8
Female; 30 300 mg 14 176 176 38.1 35.2 67 62.2 109 113.8
Female; 35 200 mg 10 183 195.1 41.6 39.2 76.1 76.5 106.9 118.6
Male; 35 100 mg 20 217.1 227.1 41.5 39.4 90.1 89.5 127 137.6
Table 2: Percent changes to body fat percentage, body fat mass 
and lean body mass
Gender/Age % Change BFP % Change BFM % Change 
LBM
Male; 44 -8.1 -9.7 4.9
Female; 30 -7.6 -7.2 4.4
Female; 35 -5.8 0.5 11
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